Emeritus Professor Michael Makris
MA, MB BS, MD, FRCPath
Clinical Medicine, School of Medicine and Population Health
Emeritus Professor of Haemostasis & Thrombosis
m.makris@sheffield.ac.uk
+44 114 271 2760
+44 114 271 2760
+44 114 226 2760
(fax)
+44 114 226 1408
(Secretary: Claire Warsop)
The Medical School
Full contact details
Emeritus Professor Michael Makris
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries, please contact – iicd-om-operational@sheffield.ac.uk
I joined the University of Sheffield in 1989 as a Lecturer in Haematology. Following completion of my haematology training I was appointed initially Senior Lecturer in 1994 followed by Reader in Haemostasis and Thrombosis in 2002.
I became Professor of Haemostasis & Thrombosis in 2013. I am the president of the European Association for Haemophilia and Allied Disorders (EAHAD). I retired from the University at the end of March 2022 but continue to work at the Sheffield Teaching Hospitals NHS Foundation Trust as a Consultant Haematologist specialising in Haemostasis andThrombosis.
- Research interests
-
My research activities are in the area of haemostasis and thrombosis centring around a number of areas:
- The use of global coagulation assays (thrombin generation estimation and thromboelastography) for the diagnosis and management of inherited and acquired haemostatic and thrombotic disorders.
- The role of different coagulation and chromogenic assays in the accurate assessment of FVIII:C.
- The molecular pathogenesis and diagnosis of inherited platelet defects with special emphasis on Glanzmann´s thrombasthenia and MYH-9 related thrombocytopenias.
- The natural history and management of chronic hepatitis C in haemophilia.
- Adverse event reporting in patients with inherited bleeding disorders. I am the project leader of the EUHASS system.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Erratum to Fischer et al. “Inhibitor development in nonsevere haemophilia across Europe” (Thromb Haemost 2015; 114: 670-675). Thrombosis and Haemostasis, 115(03), 684-684.
- Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 114(4), 670-675. View this article in WRRO
- Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 113(05), 968-975. View this article in WRRO
- Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.. J Hepatol, 60(1), 39-45.
- Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. ARTERIOSCL THROM VAS, 25(9), 1992-1997.
- Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J THROMB HAEMOST, 3(3), 459-464.
- Familial thrombophilia and lifetime risk of venous thrombosis. J THROMB HAEMOST, 2(9), 1526-1532.
- Hereditary thrombophilia and fetal loss: a prospective follow-up study. J THROMB HAEMOST, 2(4), 592-596.
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors.. Cochrane Database Syst Rev(2), CD004449.
- Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.. Thromb Haemost, 88(3), 387-388.
- Recurrent miscarriage: aetiology, management and prognosis.. Hum Reprod Update, 8(5), 463-481.
All publications
Journal articles
- Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: multicentre observational study in the UK. British Journal of Haematology.
- Phase 1–2 trial of AAVS3 gene therapy in patients with hemophilia B. New England Journal of Medicine, 387(3), 237-247.
- Natural history of PF4 antibodies in vaccine induced immune thrombocytopenia and thrombosis. Blood.
- Cardiovascular disease in hereditary haemophilia : the challenges of longevity. British Journal of Haematology. View this article in WRRO
- Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al.. J Thromb Haemost, 20(2), 542-543.
- Sorting Nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes. Haematologica.
- Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). The Lancet Regional Health - Europe, 12, 100274-100274.
- The 2021 von Willebrand disease guidelines: Clarity and controversy.. Haemophilia, 28(1), 1-3.
- Rare missense variants in Tropomyosin‐4 (
TPM4
) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding. Journal of Thrombosis and Haemostasis, 20(2), 478-485.
- Caution in using the activated partial thromboplastin time to monitor argatroban in COVID-19 and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Clinical and Applied Thrombosis/Hemostasis, 27.
- Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?. The Lancet, 398(10313), 1801-1801.
- Vaccine-induced immune thrombotic thrombocytopenia. The Lancet Haematology. View this article in WRRO
- Vaccine‐induced immune thrombotic thrombocytopenia (VITT) ‐ update on diagnosis and management considering different resources. Journal of Thrombosis and Haemostasis.
- How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry. Blood, 138(Supplement 1), 1016-1016.
- Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow-up Study of the B-Amaze Program. Blood, 138(Supplement 1), 3967-3967.
- Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia. View this article in WRRO
- Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK — a multicentre observational study. British Journal of Haematology.
- Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. New England Journal of Medicine.
- Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 5(5).
- Evaluation of laboratory assays for anti-Platelet Factor 4 antibodies after ChAdOx1 nCOV-19 vaccination.. J Thromb Haemost.
- Disruptive technology and hemophilia care : the multiple impacts of emicizumab. Research and Practice in Thrombosis and Haemostasis.
- Viral hepatitis in haemophilia: historical perspective and current management. British Journal of Haematology.
- Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT). Research and Practice in Thrombosis and Haemostasis.
- The effect of DOAC‐Stop® on several oral and parenteral anticoagulants. International Journal of Laboratory Hematology.
- Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia.
- Management of COVID‐19‐associated coagulopathy in persons with haemophilia. Haemophilia.
- Effect of anticoagulants on fibrin clot structure: a comparison between vitamin K antagonists and factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis.
- The Cardiac Complications of COVID-19; Many Publications, Multiple Uncertainties. Vascular Biology.
- Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. Thrombosis Research.
- COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clinical and Applied Thrombosis/Hemostasis, 26. View this article in WRRO
- Evolution of Haemophilia Care in Europe: 10 years of the principles of care. Orphanet Journal of Rare Diseases, 15(1).
- Staying updated on COVID‐19 : social media to amplify science in thrombosis and haemostasis. Research and Practice in Thrombosis and Haemostasis. View this article in WRRO
- Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study.. Blood Transfus.
- The World Federation of Hemophilia Annual Global Survey 1999‐2018. Haemophilia, 26(4), 591-600.
- Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica, 105(8), 2038-2043.
- Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic. British Journal of Haematology, 189(6), 1038-1043.
- Gene therapy 1·0 in haemophilia: effective and safe, but with many uncertainties. The Lancet Haematology, 7(3), e186-e188.
- Twitter and Haemophilia. Haemophilia, 26(2), 181-182.
- Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia. Haematologica, 105(3), 536-538. View this article in WRRO
- Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews. View this article in WRRO
- Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders. HemaSphere, 3(5). View this article in WRRO
- Establishing the prevalence and prevalence at birth of hemophilia in males : a meta-analytic approach using national registries. Annals of Internal Medicine. View this article in WRRO
- Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). Psychology Research and Behavior Management, 12, 741-752. View this article in WRRO
- Real‐life experience in switching to new extended half‐life products at European haemophilia centres. Haemophilia. View this article in WRRO
- Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors. Blood Coagulation & Fibrinolysis. View this article in WRRO
- Emicizumab and thrombosis : the story so far. Journal of Thrombosis and Haemostasis, 17(8), 1269-1272. View this article in WRRO
- Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 3(3), 528-541.
- Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Patient Preference and Adherence, Volume 13, 969-979. View this article in WRRO
- Reply to Comment on: Inherited Thrombophilia and Pregnancy Complications: Should We Test?. Seminars in Thrombosis and Hemostasis, 45(05), 555-556.
- How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia. View this article in WRRO
- Publishing in Haemophilia. Haemophilia, 25(2), 181-182.
- Erratum: Inherited Thrombophilia and Pregnancy Complications: Should We Test?. Seminars in Thrombosis and Hemostasis, 45(01), e1-e1.
- Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. Research and Practice in Thrombosis and Haemostasis, 3(1), 12-14. View this article in WRRO
- Inherited Thrombophilia and Pregnancy Complications: Should We Test?. Seminars in Thrombosis and Hemostasis, 45(01), 050-060.
- The 1st
WFH
Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 25(2), 189-194.
- Haemophilia and ageing. British Journal of Haematology. View this article in WRRO
- Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).. International Journal of Laboratory Hematology. View this article in WRRO
- Measurement of extended half-life recombinant factor IX products in clinical practice.. International Journal of Laboratory Hematology. View this article in WRRO
- The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 16(12), 2530-2533. View this article in WRRO
- Comparative analysis of marketed factor VIII products: comment. Journal of Thrombosis and Haemostasis. View this article in WRRO
- A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia.. Research and Practice in Thrombosis and Haemostasis, 2(4), 640-652. View this article in WRRO
- Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. Research and Practice in Thrombosis and Haemostasis. View this article in WRRO
- Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. Journal of Clinical Pathology. View this article in WRRO
- The reversal of anticoagulation in clinical practice. Clinical Medicine, 18(4), 314-319. View this article in WRRO
- Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Hemostasis, 2(3), 535-548. View this article in WRRO
- Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. View this article in WRRO
- Hemophilia gene therapy is effective and safe. Blood, 131(9), 952-953.
- A golden age for Haemophilia treatment?. Haemophilia, 24(2), 175-176.
- Severe Wound Healing Impairment in a Patient with Dysfibrinogenaemia. Thrombosis and Haemostasis, 118(02), 430-432.
- Haemophilia of the third age. Haemophilia, 24(1), 15-16. View this article in WRRO
- Pharmacokinetics, Safety and Efficacy of a Recombinant Factor IX product, Trenonacog Alfa in Previously Treated Haemophilia B Patients. Haemophilia. View this article in WRRO
- Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis. View this article in WRRO
- Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories. International Journal of Laboratory Hematology.
- Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis.
- Von Willebrand disease and extra-intestinal angiodysplasia. Haemophilia, 23(4), e354-e355. View this article in WRRO
- The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia.
- First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.. Haemophilia.
- SIPPET trial: the answers. Haemophilia, 23(3), 344-345. View this article in WRRO
- A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment. International Journal of Laboratory Hematology. View this article in WRRO
- Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.. Int J Lab Hematol.
- Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology. View this article in WRRO
- Thrombosis in Inherited Fibrinogen Disorders. Transfusion Medicine and Hemotherapy, 44(2), 70-76. View this article in WRRO
- Hepatitis C in haemophilia: time for treatment for all. Haemophilia, 23(2), 180-181. View this article in WRRO
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia, 23(2), 255-263. View this article in WRRO
- Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia, 23(1), e1-e7.
- The current state of adverse event reporting in hemophilia. Expert Review of Hematology. View this article in WRRO
- New findings on inhibitor development: from registries to clinical studies. Haemophilia, 23, 4-13.
- Inhibitor development in haemophilia. Haemophilia, 23(S1), 3-3.
- Transient inherited antithrombin deficiency: a real phenomenon?. Thrombosis and Haemostasis. View this article in WRRO
- Summary report of the First International Conference on inhibitors in haemophilia A.. Blood Transfus, 1-9.
- Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia, 22(5), 806-812. View this article in WRRO
- Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with haemophilia. Journal of Thrombosis and Haemostasis.
- Congenital macrothrombocytopenia is a heterogeneous disorder in India. Haemophilia, 22(4), 570-582. View this article in WRRO
- Why is it so difficult to show that prothrombin complex concentrates are superior to fresh-frozen plasma for warfarin reversal?. Blood Transfus. View this article in WRRO
- NHF-McMaster Guideline on Care Models for Haemophilia Management.. Haemophilia, 22 Suppl 3, 6-16.
- Care models in the management of haemophilia: a systematic review.. Haemophilia, 22(S3), 31-40.
- Whole Exome Sequencing Identifies Genetic Variants In Inherited Thrombocytopenia With Secondary Qualitative Function Defects. Haematologica, 101, 1170-1179. View this article in WRRO
- Prophylaxis in von Willebrand Disease: Coming of Age?. Seminars in Thrombosis and Hemostasis, 42(05), 498-506. View this article in WRRO
- Quality control of point of care INR devices is essential. BMJ, 353.
- Hemophilia A treatment: disruptive technology ahead. Blood, 127(13), 1623-1624.
- Safety surveillance in haemophilia and allied disorders. Journal of Internal Medicine, 279(6), 515-523.
- Erratum to Fischer et al. “Inhibitor development in nonsevere haemophilia across Europe” (Thromb Haemost 2015; 114: 670-675). Thrombosis and Haemostasis, 115(03), 684-684.
- Pre-operative PCC for non-bleeding patients on warfarin. Thrombosis Research, 139, 158-159.
- Correction. Anaesthesia, 71(3), 352-352.
- The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 101(2), 115-208.
- Von Willebrand factor activity assay errors. Haemophilia, 22(1), e74-e76.
- Is fresh frozen plasma as good as prothrombin complex concentrate for vitamin K antagonist reversal in acute intracerebral hemorrhage?. Annals of Neurology, 79(2), 331-332.
- Choosing and using non-steroidal anti-inflammatory drugs in haemophilia. Haemophilia, 22(2), 179-187. View this article in WRRO
- FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia, 22(1), e36-e38.
- Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 114(4), 670-675. View this article in WRRO
- Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 113(05), 968-975. View this article in WRRO
- Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology, 170(5), 640-648.
- A failure to diagnose dysfibrinogenaemia: data from multicentre studies amongst UK Neqas and PRO-RBDD project laboratories. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 442-442.
- How well can laboratories diagnose type 2N VWD? Data from a UK NEQAS (blood coagulation) exercise. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 740-740.
- Whole exome sequencing in patients with inherited thrombocytopenia and excessive bleeding is an efficient way to identify genetic variants in known and novel genes. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 19-19.
- Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation & Fibrinolysis, 26(4), 383-388.
- EUHANET update February 2015. HAEMOPHILIA, 21, 12-13.
- Management of peri-operative anti-thrombotic therapy. Anaesthesia, 70, 58-e23.
- The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia, 21(3), 338-342.
- Is the continued use of UK plasma sourced cryoprecipitate justified?. British Journal of Haematology, 168(6), 908-910.
- Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: good enough for now?. Journal of Thrombosis and Haemostasis, 12(9), 1425-1427.
- Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology.. Br J Haematol, 166(6), 830-841.
- FXI concentrate use and risk of thrombosis.. Haemophilia, 20(4), e349-e351.
- Inhibitor development according to concentrate in severe hemophilia A: 4-year results from the EUHASS registry. HAEMOPHILIA, 20, 42-42.
- Major surgery in severe hemophilia A with inhibitors using a NovoSeven/FEIBA hybrid regimen. HAEMOPHILIA, 20, 150-150.
- Assaying FVIII activity: one method is not enough, and never was.. Haemophilia, 20(3), 301-303.
- Enhancing haemophilia care through registries.. Haemophilia, 20 Suppl 4, 121-129.
- Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 123(8), e11-e22.
- Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.. Haemophilia, 20(4), 587-592.
- The European standards of Haemophilia Centres. Blood Transfusion, 12(SUPPL. 3).
- Haemophilia Centre Certification Systems: Optional or optimal choice for healthcare systems?. Blood Transfusion, 12(SUPPL. 3).
- The methodology for defining the European Standards for the certification of Haemophilia Centres in Europe. Blood Transfusion, 12(SUPPL. 3).
- Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.. J Hepatol, 60(1), 39-45.
- The European Haemophilia Network (EUHANET). Blood Transfusion, 12(SUPPL. 3).
- Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa/activated prothrombin complex concentrate hybrid regimen. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 666-667.
- Emergency reversal of vitamin K antagonists with prothrombin complex concentrate: the everyday practice. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 15-15.
- A reply.. Anaesthesia, 68(12), 1287.
- Specific And Global Coagulation Assays In The Diagnosis Of Discrepant Mild Hemophilia A. Journal of Thrombosis and Haemostasis, 98, 1980-1987.
- Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects.. Blood, 122(25), 4090-4093.
- Evaluation of a genetic analysis service for antithrombin deficiency: experience of Sheffield diagnostic genetics service. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 391-391.
- Antithrombin assays can vary in sensitivity to homozygous antithrombin Budapest III, a defect that causes heparin resistance. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 715-715.
- Influence of time delays in sample processing on protein S assays. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 970-971.
- The use of the new Siemens Innovance VWF activity assay in monitoring treatment for von Willebrand disease. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 420-421.
- Specific and global coagulation assays in the diagnosis of mild haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 704-704.
- A European certification system for haemophilia centres. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 797-797.
- European Haemophilia Network (EUHANET). JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 799-800.
- Identification of novel FLI1 mutations in two families with a platelet secretion defect. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 161-161.
- Characterization of four novel beta 3 integrin defects associated with Glanzmann's thrombasthenia. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 224-224.
- European monitoring of inhibitor development in haemophilia A and B. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 133-134.
- A new era for the Haemophilia journal.. Haemophilia, 19(4), 473-474.
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.. J Thromb Haemost, 11(9), 1655-1662.
- EVALUATION OF AN ANTI XA METHOD FOR ASSAY OF RIVAROXABAN AND RELATIONSHIP TO PROTHROMBIN TIME IN 'EX VIVO' SAMPLES. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 35, 75-76.
- Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease.. Haemophilia, 19(3), e191-e192.
- Factor VIII products and inhibitors in severe hemophilia A.. N Engl J Med, 368(15), 1456.
- Vaccination induced neutropenia.. Int J Lab Hematol, 35(5), e33.
- Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.. Haemophilia, 19 Suppl 3, 1-18.
- Current issues on pathogen safety in coagulation factor concentrates. HAEMOPHILIA, 19, 8-8.
- Euhanet: The European Haemophilia Network. HAEMOPHILIA, 19, 5-5.
- A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.. Hum Mol Genet, 22(9), 1903-1910.
- F8haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia, 19(1), 113-118.
- Enhanced surveillance of individuals identified as at increased risk of CJD in the UK thorugh iatrogenic exposure: An update. PRION, 7, 61-61.
- Switching clotting factor concentrates: Considerations in estimating the risk of immunogenicity. Haemophilia.
- Regional anaesthesia and patients with abnormalities of coagulation: The Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK. Anaesthesia.
- The World Federation of Hemophilia guideline on management of haemophilia.. Haemophilia, 19(1), 1.
- Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.. Br J Haematol, 160(6), 859-861.
- Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients.. Thromb Haemost, 109(1), 16-23.
- Guideline on the management of bleeding in patients on antithrombotic agents.. Br J Haematol, 160(1), 35-46.
- Non-O blood group: an important genetic risk factor for venous thromboembolism.. Blood Transfus, 11(2), 164-165.
- Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy.. Blood Transfus, 11(4), 500-505.
- Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).. Haemophilia, 19(1), 76-81.
- Parvovirus transmission by blood products - a cause for concern?. Br J Haematol, 159(4), 385-393.
- Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel.. Blood, 120(25), 5041-5049.
- Guidelines on the investigation and management of venous thrombosis at unusual sites.. Br J Haematol, 159(1), 28-38.
- History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia.. Eur J Haematol, 89(4), 336-339.
- Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products.. Br J Haematol, 158(4), 442-452.
- The European Haemophilia Network (EUHANET) Project. HAEMOPHILIA, 18, 12-12.
- Factor V Leiden: to test or not to test, that is the debate.. Blood Transfus, 10(3), 255-256.
- Inhibitor incidence in PUPs and PTPs: Data from the first three years of the EUHASS Project. HAEMOPHILIA, 18, 87-87.
- Cardiovascular disease history and risk factors in hemophilia patients. HAEMOPHILIA, 18, 4-5.
- Measurement of post-infusion recombinant factor IX activity by clotting and chromogenic assay. HAEMOPHILIA, 18, 105-105.
- Discrepancy of recombinant factor IX potency estimates between clotting and chromogenic assays. HAEMOPHILIA, 18, 105-105.
- Clotting factor concentrate switching and inhibitor development in hemophilia A.. Blood, 120(4), 720-727.
- Malignant disease in the haemophilic population: moving towards a management consensus?. Haemophilia, 18(5), 664-671.
- The international factor IX treatment network survey. Haemophilia, 18(3), e60-e62.
- Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 157(1), 47-58.
- Longer FVIII: the 4th generation.. Blood, 119(13), 2972-2973.
- The European Haemophilia Safety Surveillance System (EUHASS). HAEMOPHILIA, 18, 1-1.
- Use of IB1001, a new investigational recombinant factor IX, in patients with hemophilia B undergoing major surgical procedures. HAEMOPHILIA, 18, 40-41.
- Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.. Haemophilia, 18(3), e173-e187.
- Prophylaxis in haemophilia should be life-long.. Blood Transfus, 10(2), 165-168.
- Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.. Haemophilia, 18(3), e164-e172.
- Prothrombin complex concentrate-related thrombotic risk following anticoagulation reversal.. Thromb Haemost, 107(3), 599.
- History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. European Journal of Haematology, 89(4), 336-339.
- A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. Haemophilia, 18(4), 503-509.
- Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products. British Journal of Haematology, 158(4), 442-452.
- Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world. Haemophilia, 18(4), 598-606.
- How I treat inhibitors in haemophilia. Haemophilia, 18(SUPPL.4), 48-53.
- Haemophilia 2012.. Haemophilia, 18(1), 1.
- Plagiarism and haemophilia.. Haemophilia, 18(1), 2.
- Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic load.. J Thromb Haemost, 10(1), 20-22.
- Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.. Haemophilia, 18(4), 598-606.
- A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.. Haemophilia, 18(4), 503-509.
- Lack of association between polymorphisms in the interleukin-1 gene cluster and familial thrombophilia.. Thromb Res, 129(5), 629-634.
- Increased prevalence of hypertension in haemophilia patients. THROMBOSIS AND HAEMOSTASIS, 108(4), 750-755.
- Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. Blood, 118(21), 2267-2267.
- Protamine reversal of low molecular weight heparin: clinically effective?. Blood Coagul Fibrinolysis, 22(7), 565-570.
- Concentrate-related inhibitor risk: is a difference always real?. J Thromb Haemost, 9(11), 2176-2179.
- Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? The true question is: what are we looking for?. Blood Transfus, 9(4), 470-471.
- p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it.. Br J Haematol, 154(5), 618-625.
- Increased prevalence of hypertension in haemophilia patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 213-213.
- Monitoring inhibitor development in haemophilia: 2-year results of EUHASS. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 301-301.
- EUHASS: the first 2 years of adverse event monitoring in persons with inherited bleeding disorders in Europe. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 928-928.
- Malignancy associated acquired factor VII deficiency. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 804-804.
- Thrombosis in patients with factor VII deficiency after treatment with concentrate. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 935-935.
- The diagnosis and management of von Willebrand disease (VWD) associated angiodysplasia. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 664-664.
- Classification of mild platelet-based bleeding disorders using lumi-aggregometry. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 9, 795-795.
- Increased QRISK2 cardiovascular disease risk score in haemophilia patients. J THROMB HAEMOST, 9, 213-213.
- Assessment of antithrombin deficiency in the real world.. Int J Lab Hematol, 33(6), 659-660.
- Guidelines on oral anticoagulation with warfarin - fourth edition.. Br J Haematol, 154(3), 311-324.
- UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011.. Haemophilia, 17(5), e877-e883.
- Reply from the authors.. Br J Anaesth, 106(4), 607-608.
- The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.. Int J Lab Hematol, 33(2), 212-218.
- The phenotypic and genetic assessment of antithrombin deficiency.. Int J Lab Hematol, 33(3), 227-237.
- Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.. Haemophilia, 17(3), 456-462. View this article in WRRO
- Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery.. Haemophilia, 17(3), 428-432.
- Identification of new platelet phenotypes through phenotyping and targetted sequencing. HAEMOPHILIA, 17(2), 339-339.
- Pharmacokinetics of IB1001, a new recombinant factor IX. HAEMOPHILIA, 17(2), 355-355.
- Speaker Abstracts. HAEMOPHILIA, 17(2), 335-335.
- The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.. Haemophilia, 17(6), 931-937.
- Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?. Blood Transfus, 9(2), 117-119.
- p.Tyr365Cys change in factor VIII: Haemophilia A, but not as we know it. British Journal of Haematology.
- Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery. Haemophilia.
- Haemophilia 2011.. Haemophilia, 17(1), 1.
- EUHASS: The European Haemophilia Safety Surveillance system.. Thromb Res, 127 Suppl 2, S22-S25.
- Routine preoperative coagulation tests: an outdated practice?. Br J Anaesth, 106(1), 1-3.
- A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease.. Thromb Res, 127(4), 341-344.
- More on: enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.. J Thromb Haemost, 9(3), 613-614.
- Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.. Haemophilia, 17(2), 185-190.
- The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies.. Int J Lab Hematol, 33(2), 154-158.
- Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.. Blood, 116(21), 3664-3664.
- Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J THROMB HAEMOST, 8(9), 1994-2000.
- Images in haematology. Noonan syndrome associated with bleeding disorders.. Br J Haematol, 151(2), 117.
- Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?. Int J Clin Pract, 64(11), 1468-1471.
- Hepatitis and Hemophilia, 215-221.
- Src family kinases are essential for primary aggregation by G(i) -coupled receptors.. J Thromb Haemost, 8(10), 2273-2282.
- The Risk of Variant Creutzfeldt-Jakob Disease (vCJD) Among UK Patients with Bleeding Disorders, Known to Have Received Clotting Factors Linked to Donors who Subsequently Developed vCJD. PRION, 4(3), 167-167.
- Pharmacovigilance: clinical studies (adverse events). HAEMOPHILIA, 16, 29-29.
- Using a registry to monitor inhibitor development in haemophilia: first results of EUHASS. HAEMOPHILIA, 16, 47-47.
- Biovigilance and pharmacovigilance for haemophilia. HAEMOPHILIA, 16, 17-21.
- Hemophilia A and B, 61-72.
- Laboratory Tests of Hemostasis, 7-16.
- Practical Hemostasis and Thrombosis: Second Edition. Practical Hemostasis and Thrombosis: Second Edition.
- Clinical guidelines for testing for heritable thrombophilia. BRIT J HAEMATOL, 149(2), 209-220.
- Abstracts of the 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders. HAEMOPHILIA, 16(2), 386-386.
- Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. HAEMOPHILIA, 16(2), 305-315.
- Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.. J Thromb Thrombolysis, 29(2), 171-181.
- Noonan syndrome associated with bleeding disorders. British Journal of Haematology, 151(2), 117.
- Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors.. Hamostaseologie, 30(1), 29-38.
- Haemophilia 2010.. Haemophilia, 16(1), 1-2.
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. COCHRANE DB SYST REV(8).
- The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals.. Br J Haematol, 148(1), 15-25.
- Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin.. Reprod Biomed Online, 19(2), 216-220.
- Is VIII worse than IX?. Blood, 114(4), 750-751.
- Optimizing warfarin reversal - an ex vivo study. J THROMB HAEMOST, 7(7), 1123-1127.
- Pregnancy outcome in women with factor V Leiden and recurrent miscarriage.. BJOG, 116(7), 995-998.
- Thrombophilia: grading the risk.. Blood, 113(21), 5038-5039.
- Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study.. Blood, 113(17), 4110-4113.
- Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A.. Thromb Res, 123(6), 895-901.
- The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.. Int J Lab Hematol, 31(2), 189-198.
- Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin. EUR J HAEMATOL, 82(3), 208-212.
- The European Haemophilia Safety Surveillance (EUHASS) project. HAEMOPHILIA, 15(2), 620-620.
- Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR.. Blood, 112(11), 1826-1826.
- Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5.. Blood, 112(11), 1985-1985.
- Evaluation of a new venom-based clotting assay of protein C.. Int J Lab Hematol, 30(5), 437-443.
- Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. BRIT J HAEMATOL, 142(6), 946-952.
- Thrombin generation testing in routine clinical practice: are we there yet?. BRIT J HAEMATOL, 142(6), 889-903.
- An interpretative phenomenological analysis of adaptation to recurrent venous thrombosis and heritable thrombophilia: the importance of multi-causal models and perceptions of primary and secondary control.. J Health Psychol, 13(6), 776-784. View this article in WRRO
- Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.. Thromb Haemost, 100(2), 350-355.
- A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. AM J MED, 121(7), 632-636.
- Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline - Approved by the British Committee for Standards in Haematology. HAEMOPHILIA, 14(4), 671-684.
- Paracetamol/acetaminophen usage in haemophilia: more caution needed?. HAEMOPHILIA, 14(3), 434-435.
- Liver transplantation for factor XI deficiency: cure before diagnosis. HAEMOPHILIA, 14(3), 649-650.
- Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.. Blood Coagul Fibrinolysis, 19(3), 183-189.
- Mediterranean macrothrombocytopenia and phytosterolaemia/sitosterolaemia.. Haematologica, 93(2), e29.
- Hyperhomocysteinemia in women with advanced breast cancer (International Journal of Laboratory Hematology). International Journal of Laboratory Hematology, 30(1), 87.
- Altitude and coagulation activation: Does going high provoke thrombosis?. ACTA HAEMATOL-BASEL, 119(3), 156-157.
- Hyperhomocysteinemia in women with advanced breast cancer.. Int J Lab Hematol, 29(6), 421-425.
- Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.. Blood Transfus, 5(4), 204-209.
- Protein C deficiency screening using a thrombin generation assay - An upgrade. THROMB HAEMOSTASIS, 98(3), 691-692.
- Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J THROMB HAEMOST, 5(8), 1624-1629.
- TEN YEARS FOLLOW UP OF HEREDITARY HAEMORRHAGIC PARIENTS IN DENTAL PRACTICE. Journal of Thrombosis and Haemostasis, 5.
- Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. BLOOD, 109(9), 3667-3671.
- Hyperhomocysteinemia and venous thrombosis.. Semin Hematol, 44(2), 70-76.
- Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. BLOOD, 109(5), 1870-1877.
- Fatal spontaneous thrombosis of a cerebral arteriovenous malformation in a young patient with a rare heterozygous prothrombin gene mutation. Case report.. J Neurosurg, 106(2 Suppl), 143-146.
- Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.. Haemophilia, 13(1), 93-97.
- Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.. Blood, 108(11), 876-876.
- Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).. Blood, 108(11), 1047-1047.
- A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.. Blood, 108(11), 1472-1472.
- Between-batch variation of calibrator activity can significantly influence fluorogenic measurement of thrombin generation. J THROMB HAEMOST, 4(11), 2514-2516.
- Cognitive appraisals and psychological distress following venous thromboembolic disease: an application of the theory of cognitive adaptation.. Soc Sci Med, 63(9), 2395-2406.
- Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. HAEMOPHILIA, 12(5), 473-478.
- Establishment of the I-st International Genetic Reference Panel for FactorV Leiden, human gDNA. THROMB HAEMOSTASIS, 96(2), 215-219.
- Textbook of Haemophilia. Clinical and Laboratory Haematology, 28(2), 146-146.
- Home treatment of haemarthroses using a single dose regimen of recombinant activated factorVII in patients with haemophilia and inhibitors - A multi-centre, randomised, double-blind, cross-over trial. THROMB HAEMOSTASIS, 95(4), 600-605.
- Uncertain times for research on hemophilia and allied disorders. J THROMB HAEMOST, 4(3), 683-683.
- The von Willebrand disease prophylaxis network: Exploring a treatment concept [10]. Journal of Thrombosis and Haemostasis, 4(11), 2511-2512.
- Gastrointestinal bleeding in von Willebrand disease.. Thromb Res, 118 Suppl 1, S13-S17.
- Thrombin Generation Test, F1+2 and TAT Levels in Hemophiliacs.. Blood, 106(11), 3217-3217.
- UKHCDO Acquired Haemophilia Study: A Complete National Cohort.. Blood, 106(11), 322-322.
- Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. ARTERIOSCL THROM VAS, 25(9), 1992-1997.
- Is recombinant FVIIa the magic bullet in the treatment of major bleeding?. BRIT J ANAESTH, 94(5), 553-555.
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity - a rebuttal. J THROMB HAEMOST, 3(4), 818-819.
- Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J THROMB HAEMOST, 3(3), 459-464.
- Optimisation of the prothrombin complex concentrate dose for warfarin reversal. THROMB RES, 115(6), 451-453.
- Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia.. Br J Haematol, 130(2), 297-309.
- Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. BRIT J HAEMATOL, 127(2), 209-213.
- Bleeding small bowel angiodysplasia in association with aortic stenosis: A role for combined wireless capsule endoscopy and push enteroscopy?. J CLIN GASTROENTEROL, 38(9), 836-837.
- Familial thrombophilia and lifetime risk of venous thrombosis. J THROMB HAEMOST, 2(9), 1526-1532.
- Systematic review of the management of patients with haemophilia A and inhibitors.. Blood Coagul Fibrinolysis, 15 Suppl 1, S25-S27.
- Hereditary thrombophilia and fetal loss: a prospective follow-up study. J THROMB HAEMOST, 2(4), 592-596.
- Unconventional diagnosis of Normandy-type von Willebrand's disease in a blood donor.. Transfus Med, 14(2), 181-184.
- The impact of HIV on mortality rates in the complete UK haemophilia population.. AIDS, 18(3), 525-533.
- SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria?. J Thromb Haemost, 2(2), 271-274.
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors. COCHRANE DATABASE OF SYSTEMATIC REVIEWS(2).
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors.. Cochrane Database Syst Rev(2), CD004449.
- Bone marrow biopsy related haemorrhage and low molecular weight heparin. BRIT J HAEMATOL, 123(3), 562-562.
- Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha(2)beta(1). BLOOD, 102(6), 2085-2092.
- Immunization of patients with bleeding disorders.. Haemophilia, 9(5), 541-546.
- Management of excessive anticoagulation or bleeding.. Semin Vasc Med, 3(3), 279-284.
- Characterization of a new therapeutic recombinant human anti-thrombin concentrate. Journal of Thrombosis and Haemostasis, 1, P1016-P1016.
- Profile of mutations in a UK hemophilia A patient population. Journal of Thrombosis and Haemostasis, 1, P0626-P0626.
- Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction.. Blood Coagul Fibrinolysis, 14(5), 499-503.
- Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J THROMB HAEMOST, 1(5), 1112-1114.
- Unsuspected haemophilia in children with a single swollen joint.. BMJ, 326(7381), 151-152.
- Reply to escobar. British Journal of Haematology, 118(3), 926-926.
- Reversal of coumarin-induced over-anticoagulation - Reply. BRIT J HAEMATOL, 118(3), 926-926.
- Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.. Thromb Haemost, 88(3), 387-388.
- Recurrent miscarriage: aetiology, management and prognosis.. Hum Reprod Update, 8(5), 463-481.
- Kilt syndrome?. BRIT J HAEMATOL, 118(4), 1199-1200.
- An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity. BLOOD COAGUL FIBRIN, 13(2), 155-163.
- Axillary vein thrombosis in a healthy donor following platelet apheresis.. Br J Haematol, 116(2), 390-391.
- Reversal of coumarin-induced over-anticoagulation [5] (multiple letters). British Journal of Haematology, 118(3), 925-926.
- ALLOGENEIC MARROW GRAFTS FROM UNRELATED DONORS WITH CONGENITAL PERICENTRIC INVERSION OF CHROMOSOME 9. British Journal of Haematology, 116(1), 238-238.
- Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thrombosis and Haemostasis, 88(3), 387-388.
- The use of oral vitamin K for reversal of over-warfarinization.. Br J Haematol, 116(1), 237.
- Air flight-related thrombosis: reality or hype?. Br J Biomed Sci, 59(1), 2-3.
- A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. BRIT J HAEMATOL, 115(1), 145-149.
- Pathology Integrated: An A-Z of disease and its pathogenesis. British Journal of Haematology, 114(2), 492-492.
- The management of coumarin-induced over-anticoagulation Annotation.. Br J Haematol, 114(2), 271-280.
- Raised plasma homocysteine levels in women with metastatic breast cancer.. BRIT J CANCER, 85, 26-26.
- Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia.. Haemophilia, 7(4), 339-345.
- Personal practice: An approach to investigation of easy bruising.. Arch Dis Child, 84(6), 488-491.
- The management of von Willebrand's disease-associated gastrointestinal angiodysplasia.. Blood Coagul Fibrinolysis, 12(2), 143-148.
- Recent onset of bleeding and gross coagulopathy.. Postgrad Med J, 77(903), 53-58.
- Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia. AM J HEMATOL, 66(1), 67-68.
- Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. British Journal of Haematology, 111(3), 974-979.
- Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.. Clin Lab Haematol, 22(6), 351-354.
- Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.. Br J Haematol, 111(3), 974-979.
- The risk of pregnancy related thrombosis in relatives of patients with thrombophilia.. BLOOD, 96(11), 535A-535A.
- The risk of fetal loss in relatives of patients with thrombophilia.. BLOOD, 96(11), 648A-+.
- The management of von Willebrand's disease associated gastrointestinal angiodysplasia.. BLOOD, 96(11), 87B-87B.
- Monthly haemoptysis in a woman with platelet storage pool disease.. Clin Lab Haematol, 22(5), 295-296.
- Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden.. Br J Haematol, 110(1), 135-138.
- Hyperhomocysteinemia and thrombosis.. Clin Lab Haematol, 22(3), 133-143.
- Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency--partial/complete deletions and rearrangement of the antithrombin gene.. Thromb Haemost, 83(5), 715-721.
- Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S.. Blood, 95(6), 1935-1941.
- Poor reversal of low molecular weight heparin by protamine. BRIT J HAEMATOL, 108(4), 884-885.
- The diagnosis and management of acquired haemophilia. CME Bulletin Haematology, 3(1), 3-5.
- Mesenteric infarction due to combined protein C deficiency and prothrombin 20210 defects.. Postgrad Med J, 75(890), 742-743.
- New balance has been established to prevent the haemophiliacs to bleed permanently and all the time?. BLOOD, 94(10), 97B-97B.
- The heparin - Antithrombin aetiological identification ur thrombophilic syndromes.. BLOOD, 94(10), 108B-108B.
- An assessment of the efficacy and safety of a prothrombin complex concentrate (PCC) (Beriplex) in the immediate reversal of anticoagulation with warfarin.. BLOOD, 94(10), 25A-25A.
- Null alleles are not a common cause of type 1 von Willebrand disease in the British population.. Thromb Haemost, 82(4), 1373-1375.
- Evaluation of ProC global: A global screening assay for investigating the protein C pathway. THROMB HAEMOSTASIS, 849-849.
- Infection with the transfusion transmitted virus (TTV) and heterozygosity for the common haemochromatosis mutation C282Y are not associated with more severe liver disease in chronic hepatitis C (HCV) infected haemophiliacs. THROMB HAEMOSTASIS, 475-475.
- Elevated factor VIII levels are indicative of increased factor VIII activation in subjects with familial thrombophilia. THROMB HAEMOSTASIS, 756-756.
- Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency. THROMB HAEMOSTASIS, 517-518.
- The 46 allele of the-675 4G/5G dimorphism in the PAI-1 promoter increases thrombotic risk in patients with factor V Leiden. THROMB HAEMOSTASIS, 668-668.
- Increased prevalence of compound heterozygosity for the C677T and A1289C dimorphisms in the methylene tetrahydrofolate reductase gene in patients with factor V Leiden and venous thrombosis. THROMB HAEMOSTASIS, 71-71.
- Pseudohomozygous Factor V Leiden. THROMB HAEMOSTASIS, 266-267.
- Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin.. Haemophilia, 5(4), 270-272.
- The common haemochromatosis mutation does not increase the risk of thrombosis in patients with factor V Leiden. BRIT J HAEMATOL, 105(3), 842-843.
- Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate.. Haemophilia, 5(3), 209-212.
- Retinal vein occlusion, the contraceptive pill and the prothrombin 20210A allele. EYE, 13, 269-269.
- Rapid detection of factor IX gene mutations using conformation sensitive gel electrophoresis.. BRIT J HAEMATOL, 105, 36-36.
- A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis.. Br J Haematol, 104(4), 915-918.
- Alternative models of delivery of anticoagulant services.. Semin Thromb Hemost, 25(1), 33-36.
- Acute liver failure induced by alcohol and paracetamol in an HCV-infected haemophiliac.. Br J Haematol, 103(3), 891-893.
- Diagnosis and thrombotic risk in a cohort with genetically confirmed protein S deficiency.. BLOOD, 92(10), 561A-561A.
- Hematologic Pathophysiology. . Edited by F RED J. S CHIFFMAN. Lippincott-Raven, Philadelphia, 1998. Pp. 388. $25.00.. British Journal of Haematology, 103(2), 594-594.
- Antithrombins Wibble and Wobble (T85M/K): Archetypal Conformational Diseases With In Vivo Latent-Transition, Thrombosis, and Heparin Activation. Blood, 92(8), 2696-2706.
- Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation.. Blood, 92(8), 2696-2706.
- Book Review. European Journal of Vascular and Endovascular Surgery, 16(2), 176-177.
- A novel mutation in intron K of the PROS1 gene causes aberrant RNA splicing and is a common cause of protein S deficiency in a UK thrombophilia cohort.. Thromb Haemost, 79(6), 1086-1091.
- Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis.. Br J Haematol, 101 Suppl 1, 18-20.
- Norethisterone therapy for bleeding due to gastrointestinal telangiectases in Glanzmann's thrombasthenia.. Br J Haematol, 100(3), 594-596.
- Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia.. Thromb Haemost, 78(6), 1426-1429.
- Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1+2. BLOOD COAGUL FIBRIN, 8(8), 485-489.
- The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss.. Br J Haematol, 98(3), 660-661.
- The relationship between 26 blood group antigens and factor VIII levels in normal individuals. THROMB HAEMOSTASIS, P2566-P2566.
- Liver biopsy in haemophilia. BRIT J HAEMATOL, 97(3), 689-690.
- Hepatitis G does not lead to more severe liver disease in hepatitis C co-infected patients with congenital bleeding disorders. THROMB HAEMOSTASIS, P1842-P1842.
- Influence of founder effect and mutations causing borderline phenotypes on the prevalence of antithrombin deficiency in thrombophilic patients. THROMB HAEMOSTASIS, P1764-P1764.
- The C677F polymorphism in the methylene tetrahydrofolate reductase gene: Interaction with factor V Leiden in thrombophilia patients. THROMB HAEMOSTASIS, P2154-P2154.
- Co-inheritance of the 20210A allele of the prothrombin gene increases the thrombotic risk in subjects with familial thrombophilia. THROMB HAEMOSTASIS, SC672-SC672.
- The prothrombin 20210 G->A variant is associated with increased levels of prothrombin and increased incidence of venous thrombosis. THROMB HAEMOSTASIS, O1546-O1546.
- Interferon-alpha treatment and formation of factor VIII antibodies. ANN INTERN MED, 126(10), 829-829.
- Increased Fetal Loss in Women With Heritable Thrombophilia. Obstetrical & Gynecological Survey, 52(3), 155-156.
- The natural history of chronic hepatitis C in haemophiliacs. BRIT J HAEMATOL, 96(4), 875-876.
- Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.. Thromb Haemost, 77(3), 477-480.
- Familial thrombophilia: genetic risk factors and management.. J INTERN MED SUPPL, 740, 9-15.
- In vivo coagulation activation following infusion of highly purified factor XI concentrate.. Br J Haematol, 96(2), 293-297.
- Interferon-α treatment and formation of factor VIII antibodies [3] (multiple letters). Annals of Internal Medicine, 126(10), 829-830.
- Liver biopsy in haemophilia [6] (multiple letters). British Journal of Haematology, 97(3), 689-691.
- Familial thrombophilia: genetic risk factors and management.. J Intern Med Suppl, 740, 9-15.
- Increased fetal loss in women with heritable thrombophilia.. Lancet, 348(9032), 913-916.
- P9 The molecular basis of antithrombin deficiency. Blood Coagulation & Fibrinolysis, 7(7), 734-734.
- Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Blood, 88(5), 1700-1707.
- The natural history of chronic hepatitis C in haemophiliacs.. Br J Haematol, 94(4), 746-752.
- Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden.. Blood, 88(5), 1700-1707.
- Emergency oral anticoagulant reversal: The necessity for prothrombin complex concentrates. BRIT J HAEMATOL, 93, 40-40.
- Pregnancy in women with thrombophilia: Incidence of thrombosis and pregnancy outcome. BRIT J HAEMATOL, 93, 528-528.
- Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques.. Thromb Haemost, 75(6), 959-964.
- Factors influencing the development of cirrhosis and liver failure in patients with congenital bleeding disorders and chronic hepatitis C.. BRIT J HAEMATOL, 93, 188-188.
- Emergency oral anticoagulant reversal: The necessity for prothrombin complex concentrates.. BRIT J HAEMATOL, 93, 22-22.
- Coagulation activation following infusions of a factor XI concentrate.. BRIT J HAEMATOL, 93, 39-39.
- Pregnancy in women with thrombophilia - Incidence of thrombosis and pregnancy outcome.. BRIT J HAEMATOL, 93, 112-112.
- The molecular basis of protein S deficiency in four unrelated kindred.. BRIT J HAEMATOL, 93, 17-17.
- Warfarin induced skin necrosis associated with activated protein C resistance. THROMB HAEMOSTASIS, 75(3), 523-524.
- The natural history of chronic hepatitis C in haemophiliacs. British Journal of Haematology, 94(4), 746-752.
- Identification of two protein S gene mutations in two kindred with deficiency of protein S and APC resistance. BLOOD, 86(10), 1426-1426.
- VARIATION OF THE HEPATITIS-C VIRUS 5' NONCODING REGION - IMPLICATIONS FOR SECONDARY STRUCTURE, VIRUS DETECTION AND TYPING. J GEN VIROL, 76, 1749-1761.
- APPLICATION OF THE METHOD OF ROSENDAAL ET-AL TO THE ASSESSMENT OF ANTICOAGULANT CONTROL IN A NUMBER OF CLINICAL SETTINGS. THROMB HAEMOSTASIS, 73(6), 1115-1115.
- THE INTRODUCTION OF CLINICAL GUIDELINES AND THEIR EFFECT ON INPATIENT ANTICOAGULANT CONTROL. THROMB HAEMOSTASIS, 73(6), 1116-1116.
- THE USE OF ANTITHROMBIN-III CONCENTRATE IN PREGNANT-WOMEN WITH FAMILIAL ATIII DEFICIENCY. THROMB HAEMOSTASIS, 73(6), 1300-1300.
- THE RELATIONSHIP BETWEEN ANTI-XA LEVEL AND BLEEDING IN OVERANTICOAGULATED PATIENTS. THROMB HAEMOSTASIS, 73(6), 976-976.
- COMPARISON OF THE THROMBOTIC RISK IN GROUPS HETEROZYGOUS AND HOMOZYGOUS FOR THE FACTOR-V-G1691A MUTATION CONFERRING APC RESISTANCE. THROMB HAEMOSTASIS, 73(6), 1367-1367.
- Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease.. Blood, 85(5), 1259-1262.
- The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C.. Br J Haematol, 88(4), 845-848.
- Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.. Br J Haematol, 88(1), 201-203.
- Increased soluble IL-2 receptor levels in HCV-infected haemophiliacs: a possible indicator of liver disease severity.. Br J Haematol, 87(2), 419-421.
- FIRST REPORT ON UK DATABASE OF HEMOPHILIA-B MUTATIONS AND PEDIGREES. THROMB HAEMOSTASIS, 71(5), 563-570.
- Peripheral mononuclear cells of haemophiliacs with chronic liver disease are infected with replicating hepatitis C virus.. Br J Haematol, 87(1), 215-217.
- LONG-TERM MANAGEMENT AFTER SPLENECTOMY - LIFELONG PENICILLIN UNPROVED IN TRIALS. BRIT MED J, 308(6921), 131-132.
- Chronic hepatitis in haemophilia.. Blood Rev, 7(4), 243-250.
- THE USE OF CLOTTING FACTOR CONCENTRATES IN THE REVERSAL OF WARFARIN IN PATIENTS WITH LIFE-THREATENING BLEEDS. THROMB HAEMOSTASIS, 69(6), 982-982.
- Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood, 81(7), 1898-1902.
- Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients.. Blood, 81(7), 1898-1902.
- AUDIT OF THE FREQUENCY AND CLINICAL-RESPONSE TO EXCESSIVE ORAL ANTICOAGULATION. BRIT J HAEMATOL, 84, 57-57.
- THE USE OF CLOTTING FACTOR CONCENTRATES IN THE REVERSAL OF WARFARIN IN PATIENTS WITH LIFE-THREATENING BLEEDS. BRIT J HAEMATOL, 84, 16-16.
- Interferon alfa for chronic hepatitis C in haemophiliacs.. Gut, 34(2 Suppl), S121-S123.
- DOES HIV-INFECTION ACCELERATE MALIGNANT TRANSFORMATION OF PREMALIGNANT STATES. EUR J HAEMATOL, 49(4), 220-220.
- NEED FOR 2ND-GENERATION ANTI-HCV TESTING IN HEMOPHILIA. LANCET, 339(8791), 501-502.
- A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood, 78(7), 1672-1677.
- A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.. Blood, 78(7), 1672-1677.
- Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.. Blood Coagul Fibrinolysis, 2(5), 637-641.
- THE DEVELOPMENT OF ANTIPHOSPHOLID ANTIBODIES (APA) IN HEMOPHILIA IS STRONGLY LINKED TO INFECTION WITH HEPATITIS-C. THROMB HAEMOSTASIS, 65(6), 1257-1257.
- LIVER-TRANSPLANTATION IN HEMOPHILIA. THROMB HAEMOSTASIS, 65(6), 1157-1157.
- A FUNCTIONAL ASSAY OF PROTEIN-S. THROMB HAEMOSTASIS, 65(6), 1202-1202.
- BIOCHEMICAL CRITERIA FOR NON-A-HEPATITIS, NON-B-HEPATITIS (NANBH) AND ASSAYS FOR HEPATITIS-C VIRUS (HCV) RNA AND ANTIBODY FOLLOWING 1ST EXPOSURE TO CLOTTING FACTOR CONCENTRATE. THROMB HAEMOSTASIS, 65(6), 823-823.
- IMMUNOLOGICAL ABNORMALITIES DUE TO HEPATITIS-C INFECTION IN HIV ANTIBODY NEGATIVE HEMOPHILIACS. THROMB HAEMOSTASIS, 65(6), 996-996.
- CLINICAL USE AND MONITORING OF ACTIVATED RECOMBINANT FACTOR FVII CONCENTRATE (RFVIIA) IN HEMOPHILIA A PATIENTS WITH FACTOR-VIII INHIBITORS. THROMB HAEMOSTASIS, 65(6), 677-677.
- THROMBOGENICITY OF PROTHROMBIN COMPLEX CONCENTRATES, RELATION TO LIVER-DISEASE. THROMB HAEMOSTASIS, 65(6), 1166-1166.
- BIAS DUE TO PUBLICATION OF POSITIVE RESULTS WITH TREATMENTS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA. LANCET, 337(8749), 1106-1107.
- Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications.. Diabet Med, 8(4), 322-329.
- The chest radiograph appearances seen following high dose chemotherapy and autologous bone marrow transplantation for resistant malignant lymphoma.. Br J Radiol, 64(758), 103-106.
- DEMONSTRATION OF VIREMIA PATTERNS IN HEMOPHILIACS TREATED WITH HEPATITIS-C-VIRUS-CONTAMINATED FACTOR-VIII CONCENTRATES. LANCET, 336(8722), 1022-1025.
- Evans' syndrome associated with dermatomyositis.. Ann Rheum Dis, 49(10), 793-794.
- Safety of antithrombin III concentrate [letter; comment]. Blood, 76(3), 649-650.
- SAFETY OF ANTITHROMBIN-III CONCENTRATE. BLOOD, 76(3), 649-649.
- INFLUENCE OF INTERFERON-ALPHA THERAPY ON HEPATITIS-C HISTOLOGY IN HEMOPHILIACS. J PATHOL, 161(4), A354-A354.
- Prevention of hepatitis C virus infection in haemophiliacs. The Lancet, 336(8706), 62-63.
- PREVENTION OF HEPATITIS-C VIRUS-INFECTION IN HEMOPHILIACS - REPLY. LANCET, 336(8706), 63-63.
- DETECTION BY PCR OF HEPATITIS-C VIRUS IN FACTOR-VIII CONCENTRATES. LANCET, 335(8703), 1473-1473.
- Hepatitis C antibody and chronic liver disease in haemophilia.. Lancet, 335(8698), 1117-1119.
- A PROSPECTIVE RANDOMIZED CROSS OVER STUDY OF RECOMBINANT ALPHA INTERFERON IN CHRONIC HEPATITIS-C IN HEMOPHILIA. GUT, 31(5), A591-A591.
- Hepatitis C antibody and chronic liver disease in haemophilia. Lancet, 335, 1117-1119.
- A biopsy-controlled trial of interferon alfa-2b in chronic NANB hepatitis in hemophiliacs. Journal of Hepatology, 11(SUPPL. 1).
- TEICOPLANIN ADMINISTRATION IN PATIENTS EXPERIENCING REACTIONS TO VANCOMYCIN. J ANTIMICROB CHEMOTH, 23(5), 810-812.
- Von Willebrand Disease: Gaining a global perspective. Haemophilia.
- Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia.
- Managing prostatic illness in persons with haemophilia. Haemophilia.
- Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances.
- Anti‐PF4 testing for vaccine‐induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021. Journal of Thrombosis and Haemostasis.
- Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia.
- Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia.
- The EHA Research Roadmap: Platelet Disorders. HemaSphere, 5(7), e601-e601.
- Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia.
- ‘Haemophilia Guidelines for All’: A new ambition of the World Federation of Haemophilia (WFH). Haemophilia.
- Management of comorbidities in haemophilia. Haemophilia.
- Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews.
- Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia, 7(4), 339-345.
- Clinical Outcomes and the Impact of Oral Anticoagulants Prior to Diagnosis of COVID-19 on Clinical Outcomes in Patients Admitted to Hospitals in the UK – a Multicentre Observational Study. SSRN Electronic Journal.
Chapters
- Venous thromboembolism: deep vein thrombosis and pulmonary embolism, Oxford Textbook of Fundamentals of Surgery (pp. 649-655). Oxford University Press
- Use of the Polymerase Chain Reaction to Detect Viral Contamination of Clotting Factor Concentrates, 24. Hämophilie-Symposion (pp. 60-67). Springer Berlin Heidelberg
- Inherited Platelet Defects, Inherited Bleeding Disorders in Women 2e (pp. 133-152). John Wiley & Sons, Ltd
- Hemophilia A and B, Practical Hemostasis and Thrombosis (pp. 79-93). John Wiley & Sons, Ltd
- Laboratory Tests of Hemostasis, Practical Hemostasis and Thrombosis (pp. 12-26). John Wiley & Sons, Ltd
- Reference Ranges, Practical Hemostasis and Thrombosis (pp. 444-451). John Wiley & Sons, Ltd
- Viral Hepatitis and Hemophilia, Textbook of Hemophilia (pp. 263-271). John Wiley & Sons, Ltd
- Hepatitis and Hemophilia, Viral Hepatitis (pp. 486-493). John Wiley & Sons, Ltd
- Appendix 1: Reference Ranges, Practical Hemostasis and Thrombosis (pp. 297-304). Wiley-Blackwell
- Laboratory Tests of Hemostasis, Practical Hemostasis and Thrombosis (pp. 8-17). Blackwell Publishing Ltd
- Hemophilia A and B, Practical Hemostasis and Thrombosis (pp. 39-50). Blackwell Publishing Ltd
- Appendices: Normal Ranges, Practical Hemostasis and Thrombosis (pp. 209-213). Blackwell Publishing Ltd
- Appendices: Useful Websites, Practical Hemostasis and Thrombosis (pp. 214-215). Blackwell Publishing Ltd
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors John Wiley & Sons, Ltd
Conference proceedings papers
- Glanzmann Thrombocythaemia with very mild bleeding phenotype. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 143-143)
- UK EHL outcomes registry: First report on baseline pain and quality of life. HAEMOPHILIA, Vol. 25 (pp 38-38)
- Establishment of a UK registry for haemophilia patients switched to extended half-life clotting factor concentrates: 1 year update. HAEMOPHILIA, Vol. 24 (pp 39-39)
- Reduced cardiovascular events in haemophilia - Results from a 5 year prospective study. HAEMOPHILIA, Vol. 24 (pp 33-34)
- The FIX C assessment of extended half-life recombinant factor IX products in clinical practice. HAEMOPHILIA, Vol. 24 (pp 56-56)
- A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model. BLOOD, Vol. 130
- EUHANET, European Reference Networks and EuroBloodNet. HAEMOPHILIA, Vol. 23 (pp 11-12)
- Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, Vol. 128(22) (pp 207-207)
- Prothrombin complex concentrate (PCC) related thrombosis: A systematic review. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 52-52)
- C0327: Pregnancy May Falsely Reduce Antithrombin Antigen Levels in Latex-Based Assays. Thrombosis Research, Vol. 133 (pp S109-S109)
- Factor IX assays in patients receiving factor IX concentrate therapy; data from a UK NEQAS (Blood Coagulation) exercise. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 9-9)
- An automated antithrombin antigen assay on instrumentation laboratory ACL top analyser. THROMBOSIS RESEARCH, Vol. 130 (pp S182-S182)
- An automated progressive assay of antithrombin. THROMBOSIS RESEARCH, Vol. 130 (pp S182-S183)
- Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: Repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia, Vol. 18(6) (pp 881-887)
- Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. BLOOD, Vol. 118(21) (pp 984-985)
- Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients. BLOOD, Vol. 116(21) (pp 1504-1504)
- Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients. BLOOD, Vol. 116(21) (pp 1504-1504)
- Heparin resistance and antithrombin deficiency. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 149 (pp 14-14)
- Phenotypic approaches to gene mapping in platelet function disorders. HAMOSTASEOLOGIE, Vol. 30(1) (pp 29-38)
- Thrombin generation is normal in most patients with cirrhosis despite a prolonged INR. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 145 (pp 4-5)
- Factor XIII deficiency: effective haemostasis despite treatment for the wrong diagnosis. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 145 (pp 37-37)
- Gastrointestinal bleeding due to angiodysplasia in patients with inherited platelet function disorders. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 145 (pp 34-35)
- Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs > 4.5. BLOOD, Vol. 112(11) (pp 693-693)
- Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR. BLOOD, Vol. 112(11) (pp 643-644)
- Platelet-activating anti-platelet factor 4/polyanion antibodies without preceding heparin therapy: A transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT").. BLOOD, Vol. 108(11) (pp 311A-312A)
- A novel Protac (R)-modified thrombin generation assay to identify individuals at higher thrombotic risk.. BLOOD, Vol. 108(11) (pp 425A-426A)
- Reversal of anticoagulation as assessed by thrombin generation measurement.. BLOOD, Vol. 108(11) (pp 263A-263A)
- Poor correlation in thrombin generation estimation between ROTEM thromboelastometry and the fluorogenic thrombogram in normal subjects. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 42-42)
- Response to antiviral therapy in patients with congenital bleeding disorders infected with hepatitis C. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 85-86)
- The natural history of hepatitis C in patients with bleeding disorders. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 20-20)
- Factor VIII concentration and thrombin generation determination. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 40-41)
- UKHCDO acquired haemophilia study: A complete national cohort.. BLOOD, Vol. 106(11) (pp 98A-98A)
- Clinical use of protamine for the emergency reversal of anticoagulation with low molecular weight heparin (LMWH). BRITISH JOURNAL OF HAEMATOLOGY, Vol. 129 (pp 17-17)
- Haemoperitoneum associated with ovulation in women with autosomal recessive bleeding disorders. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 129 (pp 57-57)
- Elevated factor VIII : C levels in patients with pulmonary hypertension. A marker of endothelial dysfunction?. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 46-46)
- Gene defects in patients with factor XI deficiency. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 35-35)
- Elevated factor FVIII: C levels as a marker of endothelial dysfunction in patients with pulmonary hypertension. THORAX, Vol. 58 (pp 9-9)
- Lack of classical thrombophilic risk factors in cerebral venous thrombosis.. BLOOD, Vol. 102(11) (pp 115B-115B)
- Conformation sensitive gel electrophoresis detects mutations in most patients with factor XI deficiency.. BLOOD, Vol. 102(11) (pp 309A-309A)
- The use of two plasma derived factor VIII concentrates in type 2 a von Willebrand's disease (VWD).. BLOOD, Vol. 102(11) (pp 99B-99B)
- Thromboprophylaxis reduces the risk of fetal loss in women with hereditary thrombophilia.. BLOOD, Vol. 100(11) (pp 273A-273A)
- A pharmacokinetic model for dosing of rh AT by continuous infusion in patients with hereditary AT deficiency.. BLOOD, Vol. 100(11) (pp 122B-122B)
- Polymorphisms in the interleukin-1 (IL-1) gene cluster do not contibute to thrombotic risk in patients with heritable thrombophilia.. BLOOD, Vol. 100(11) (pp 271A-271A)
- A comparison of two coagulation factor concentrates in type 2A and acquired von Willebrand's disease (VWD).. BLOOD, Vol. 100(11) (pp 494A-494A)
- Successful use of desmopressin (DDAVP) in pregnant women with inherited storage pool disease. HAEMOPHILIA, Vol. 6 (pp 28-28)
- Null alleles are not a common cause of type 1 vonWillebrand's disease. BRIT J HAEMATOL, Vol. 102(1) (pp 15-15)
- Mutation at Arg611 in the von Willebrand factor gene results in unclassifiable type 2 von Willebrand disease. THROMB HAEMOSTASIS (pp P2665-P2665)
- A PROSPECTIVE RANDOMIZED CONTROLLED LIVER-BIOPSY STUDY OF RECOMBINANT ALPHA-INTERFERON IN CHRONIC NON-A-NON-B HEPATITIS IN HEMOPHILIA. RECENT ADVANCES IN HEMOPHILIA CARE, Vol. 324 (pp 135-136)
Posters
- PRIMING EFFECTS OF INTERMEDIATE PURITY FVIII CONCENTRATE ON NEUTROPHIL RESPIRATORY BURST FUNCTION.
- Erratum to Fischer et al. “Inhibitor development in nonsevere haemophilia across Europe” (Thromb Haemost 2015; 114: 670-675). Thrombosis and Haemostasis, 115(03), 684-684.
- Professional activities and memberships
-
Editorial board member for British Journal of Haematology, Blood Transfusion and Journal of Thrombosis and Haemostasis.